Pfizer

(PFE)

Financial Overview

Target Price $29.04
Market Cap $144.29B
P/E Ratio 15.4
Risk Rating Medium

About Pfizer

Pfizer Inc., led by CEO Albert Bourla, is a global pharmaceutical company known for its vaccines, oncology, and internal medicine products. It gained worldwide attention for its development of the Pfizer-BioNTech COVID-19 vaccine, one of the first to be authorized globally. Under Bourla, Pfizer has accelerated R&D investments and expanded its mRNA and gene therapy platforms. The company also focuses on equitable vaccine access and global health partnerships. Pfizer remains a major force in infectious disease and chronic condition treatment.

Analyst Forecast

Pfizer is in a strategic reset phase post-COVID, with declining vaccine revenues but a strong late-stage pipeline. The company has made key acquisitions to replenish its drug portfolio and accelerate growth. Oncology and rare disease treatments are top areas of focus going forward. Cost-cutting initiatives are underway to protect margins amid revenue normalization. Valuation is compelling, though investor patience will be tested during this transition. A value-oriented play with turnaround potential.

Analysis by John Glover

John Glover

Senior Financial Analyst

Experienced financial analyst specializing in company ratings and sector performance. Delivers in-depth evaluations of financial health, growth potential, and risk exposure to support investment decisions. Skilled in ratio analysis, forecasting, and market benchmarking.

9 years of experience

Should You Buy Pfizer Stock?

This interactive tool helps you determine whether this stock fits into your investment strategy based on your portfolio size, risk tolerance, and allocation preferences.

What this calculator analyzes:

  • Risk compatibility between your profile and this stock
  • Appropriate allocation size for your portfolio
  • Diversification recommendations
  • P/E ratio context and valuation analysis

Example Analysis:

A 15.4 P/E ratio indicates this stock has a moderate valuation. With a Medium risk rating, this stock may suit moderate risk tolerance.

$1K $10M
1% 100%

⚠️ This tool is for informational purposes only. It does not constitute financial advice. Investing involves risk, including loss of capital. Always consult a licensed financial advisor before making investment decisions.